Milestone Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Milestone Pharmaceuticals Inc 公司

Milestone Pharmaceuticals Inc. 是一家总部位于加拿大的生物制药公司。该公司专注于心血管药物的开发和商业化。其主要候选产品依曲帕米是一种强效速效钙通道阻滞剂，该公司设计并正在开发一种速效鼻喷雾剂，供患者使用。该公司还专注于开发依曲帕米用于治疗阵发性室上性心动过速 (PSVT)，随后用于治疗心房颤动伴快速心室率 (AFib-RVR) 和其他心血管适应症。

Milestone Pharmaceuticals Inc简介



公司代码MIST

公司名称Milestone Pharmaceuticals Inc

上市日期May 09, 2019

CEOMr. Joseph Oliveto

员工数量33

证券类型Ordinary Share

年结日May 09

公司地址420-1111 boul. Dr.-Frederik-Philips

城市MONTREAL

上市交易所NASDAQ Global Select Consolidated

国家Canada

邮编H4M 2X6

电话15143360444

网址https://www.milestonepharma.com

公司代码MIST

上市日期May 09, 2019

CEOMr. Joseph Oliveto

Milestone Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. David Bharucha

Chief Medical Officer

78.45K

+212.30%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

69.20K

+260.35%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+333.33%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Stuart Duty

Independent Director

--

Mr. Joeseph C. Papa

Independent Director

--

Mr. Andrew Saik

Independent Director

--

Ms. Lisa M. Giles

Independent Director

--

Mr. Joseph Oliveto

President, Chief Executive Officer, Director

--

Mr. Lorenz Muller

Chief Commercial Officer

--

名称

名称/职务

职务

持股

持股变动

Dr. David Bharucha

Chief Medical Officer

78.45K

+212.30%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

69.20K

+260.35%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+333.33%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Stuart Duty

Independent Director

--

Mr. Joeseph C. Papa

Independent Director

--

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 10月30日周四

持股股东

股东类型

持股股东

占比

Trails Edge Capital Partners LP

6.27%

Simplify Asset Management Inc

3.33%

Oliveto (Joseph Gerard)

2.95%

RTW Investments L.P.

2.95%

Propel Bio Management, LLC

2.11%

其他

82.38%

持股股东

占比

Trails Edge Capital Partners LP

6.27%

Simplify Asset Management Inc

3.33%

Oliveto (Joseph Gerard)

2.95%

RTW Investments L.P.

2.95%

Propel Bio Management, LLC

2.11%

其他

82.38%

股东类型

持股股东

占比

Investment Advisor

12.62%

Individual Investor

3.61%

Investment Advisor/Hedge Fund

3.03%

Hedge Fund

2.58%

Venture Capital

2.30%

Research Firm

2.16%

Bank and Trust

0.02%

其他

73.68%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

99

19.30M

22.71%

-5.65M

2025Q2

99

14.54M

18.86%

-15.65M

2025Q1

102

12.26M

22.94%

-17.24M

2024Q4

99

25.17M

47.19%

-9.38M

2024Q3

113

29.31M

55.02%

-13.44M

2024Q2

115

30.81M

57.87%

-11.80M

2024Q1

116

31.96M

60.43%

+3.19M

2023Q4

112

18.49M

55.02%

-13.59M

2023Q3

109

20.24M

60.32%

-12.06M

2023Q2

108

21.35M

63.87%

-11.78M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Trails Edge Capital Partners LP

5.33M

6.27%

+5.33M

--

Jul 14, 2025

Simplify Asset Management Inc

990.00K

1.16%

+140.00K

+16.47%

Jun 30, 2025

Oliveto (Joseph Gerard)

2.51M

2.95%

+66.67K

+2.73%

Jul 11, 2025

RTW Investments L.P.

2.51M

2.95%

--

Jun 30, 2025

Propel Bio Management, LLC

1.79M

2.11%

+340.00K

+23.42%

Jun 30, 2025

Alta Fundamental Advisers LLC

1.40M

1.65%

-28.50K

-2.00%

Jun 30, 2025

BML Capital Management LLC

1.14M

1.34%

--

Jun 30, 2025

Morgan Stanley & Co. LLC

817.82K

0.96%

-148.10K

-15.33%

Jun 30, 2025

TD Securities, Inc.

750.00K

0.88%

--

Jun 30, 2025

Lion Point Capital, L.P.

548.81K

0.65%

--

Jun 30, 2025

持股ETF



更新时间: 11月2日周日

机构名称

占比

Simplify Propel Opportunities ETF

8.56%

SPDR S&P International Small Cap ETF

0.01%

Avantis US Small Cap Equity ETF

0%

Simplify Propel Opportunities ETF

占比8.56%

SPDR S&P International Small Cap ETF

占比0.01%

Avantis US Small Cap Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据